Neoplasms Clinical Trial
Official title:
Using Positron Emission Tomography (PET) to Predict Intracranial Tumor Growth in Neurofibromatosis Type II (NF2) Patients
Background:
- Neurofibromatosis type II (NF2) is associated with tumors of the nerves, brain, and
spinal cord. Most people with NF2 develop vestibular schwannomas, or tumors on the
hearing and balance nerves. As they grow, vestibular schwannomas can cause hearing loss
and balance problems. If they grow very large they can cause more serious problems, such
as seizures, loss of eyesight, weakness, speech problems, and problems with the sense of
touch. More research is needed into NF2 because researchers do not completely understand
why these tumors occur or what makes them grow over time.
- Currently, tumor size is measured with magnetic resonance imaging (MRI) scans. However,
MRI scans cannot predict how fast a tumor will grow. By using positron emission
tomography (PET) scanning, researchers hope to be able to predict sudden growth spurts
of tumors associated with NF2 and develop better treatment methods for this type of
cancer.
Objectives:
- To use magnetic resonance imaging and positron emission tomography to better understand the
growth of brain tumors in people with neurofibromatosis type II.
Eligibility:
- Individuals between 18 and 50 years of age who have been diagnosed with NF2 and have at
least three untreated intracranial tumors.
Design:
- This study requires an initial set of outpatient visits to the NIH Clinical Center that
will last 7 to 10 days.
- Participants will have a physical and neurological examination and blood tests at the
first visit. Participants will then have the following imaging studies to examine the
tumors:
- MRI scans of the brain
- PET scans of the brain, combined with a computed tomography (CT) scan. The PET scans
will be performed on separate days. Different contrast agents will be used for both
scans, so researchers will inform participants if they need to fast or follow other
procedures before having the scan.
- After the initial imaging studies, participants will have additional MRI scans every 6
months for 2 years to track tumor growth.
OBJECTIVE:
The objective of this prospective observational study of intracranial tumors in patients with
neurofibromatosis type 2 (NF2) is to gain insight into the use of 18F-fluoro-deoxyglucose
(FDG) and 3 -deoxy-3 -18F-fluorothymidine (FLT) positron emission tomography (PET)/computed
tomography (CT) as a predictive measure of future tumor growth patterns.
STUDY POPULATION: <TAB>
Twelve patients, ages 18-50, with a clinical or genetic diagnosis of NF2 and harboring at
least 3 unoperated intracranial tumors (meningiomas and/or vestibular schwannomas) will
participate in this study.
DESIGN:
Study participants will be evaluated with a thorough physical and neurologic examination upon
enrollment. This initial outpatient evaluation will include contrast-enhanced magnetic
resonance imaging (MRI) of the brain, FDG-PET/CT and FLT-PET/CT scans.
Subjects will be followed as outpatients for two years, during which time MRI evaluation will
be performed every six months.
OUTCOME MEASURES:
Based on data derived from this study, we hope to correlate FDG-PET/CT and FLT-PET/CT scans
with metabolic activity and cellular proliferation within tumors. These findings will help us
better forecast tumor growth and senescence. These findings should permit the safer treatment
of the subset of tumors that will grow and cause symptoms and avoid the unnecessary treatment
of lesions that will remain stable (not requiring treatment) in these patients.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
Not yet recruiting |
NCT02806557 -
Profiling Neutrophil Counts in Patients on Chemotherapy
|
N/A | |
Completed |
NCT02909348 -
Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab
|